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ABSTRACT
One component of control programmes to eliminate trachoma is the treatment of Chlamydia trachomatis
infection. A diagnosis of trachoma is based on clinical grounds, but the signs of active trachoma do not
always correlate with the presence of C. trachomatis. During a therapeutic trial, the level of C. trachomatis
infection in children with active trachoma in Guinea and Pakistan was assessed using a qualitative
commercially available PCR that targeted the C. trachomatis plasmid. The inﬂuence of the quality of
specimens on the efﬁciency of the PCR was investigated using two quantitative real-time PCRs targeting
the speciﬁc omp1 gene of C. trachomatis and human chromosomal DNA, respectively. C. trachomatis was
detected in c. 23% of children (aged 1–10 years) who presented with clinically active trachoma. Controls
showed that PCR-related problems did not inﬂuence this detection rate. For 14% of the positive samples,
C. trachomatis was detected in only one eye, with a signiﬁcantly lower mean load of bacteria. These
results suggest that epidemiological and therapeutic surveys should be conducted by sampling and
testing both eyes. Moreover, the high variability of the cell load observed in the conjunctival swabs
suggests that the effectiveness of swabbing may be questionable.
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INTRODUCTION
Trachoma caused by Chlamydia trachomatis is the
leading cause of infectious blindness worldwide
[1], and is endemic in poor rural communities in
Africa, Asia, Central America and Australia [2]. In
its early stages, trachoma appears as a follicular
conjunctivitis, evolving towards an intense tra-
chomatous inﬂammation. Trachoma may then
progress to trichiasis, which eventually leads to
blindness because of corneal opacity [3]. Several
programmes have been launched by the WHO
(especially the SAFE Strategy) in order to reduce
the incidence of blinding trachoma. The goals of
these programmes are to improve hygiene condi-
tions, to offer surgery when necessary, and to
provide antibiotic treatment to reduce the burden
and spread of C. trachomatis disease.
Assessment based on clinical signs is used to
prioritise individuals and communities for treat-
ment [4]. However, signs of active trachoma
do not always correlate with the presence of
C. trachomatis [4,5]. Thus, there are individuals
with clinical signs of active disease in whom the
organism cannot be detected and, conversely,
C. trachomatis can be found in specimens from
individuals lacking the characteristic signs and
symptoms. This raises the question of the useful-
ness of the available microbiological tests as
complementary aids for clinical diagnosis and
epidemiological surveys [6].
Among the assays available for detection of
C. trachomatis, nucleic acid ampliﬁcation tests are
more sensitive than other tests, particularly with
samples obtained from trachoma patients [7,8].
However, positivity rates using nucleic acid
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ampliﬁcation tests vary from 8% to >80% for
cases of active trachoma, raising questions con-
cerning the quality of sampling, the specimen-
processing procedures and the intrinsic limits of
these diagnostic tools. Inappropriate samples
with reduced numbers of epithelial cells, and ⁄ or
samples containing Taq polymerase inhibitors,
and ⁄ or technical limitations of specimen-process-
ing procedures, can produce false-negative
nucleic acid ampliﬁcation test results.
As part of a therapeutic trial, the presence of
C. trachomatis was investigated using the qualit-
ative Cobas Amplicor PCR assay with samples
obtained from children with active trachoma in
western Africa and Asia. The study also assessed
the quality of the conjunctival specimens by
evaluating the efﬁciency of the PCR and the
quality of sampling using two quantitative real-
time PCRs targeting, respectively, the structural
omp1 gene of C. trachomatis and a gene present as
a single copy per cell in human chromosomal
DNA.
MATERIALS AND METHODS
Study population
The study was conducted in compliance with Good Clinical
Practice procedures and the directives of the Helsinki Declar-
ation. As part of a therapeutic trial, samples (see below) were
obtained from children (males and females aged 1–10 years)
with clinically active trachoma who had not received antibi-
otics for at least 2 months. Screening for trachoma was
performed for the entire population of 21 villages in Guinea
(Kankan area, Guinea Conakry) and six villages in Pakistan
(Attock District, Punjab). Trachoma was diagnosed by trained
ophthalmologists according to the grading card supplied by
the Prevention of Blindness and Deafness Department of the
WHO (Geneva, Switzerland) [9].
Sampling
Children with trachoma were sampled with Dacron swabs
strictly according to the following procedures in order to avoid
cross-contamination. The physician in charge of sampling was
not allowed to handle pens, torches or clinical ﬁles, or to
register any data. Identiﬁcation and clinical data were regis-
tered by another independent assistant. Only disposable
material was used, and paper covers on seats were changed
after each patient in order to avoid contact between infected
biological ﬂuids and non-infected individuals. Equipment and
surfaces were cleaned with disinfectant and 1 M HCl between
collection of samples. Operators wore disposable shirts, masks,
glasses and two pairs of gloves, with the second pair being
changed for each new patient. Once the clinical diagnosis was
conﬁrmed, and after informed consent had been obtained, the
upper tarsal conjunctiva of each eye was swabbed intensely
with Dacron swabs. The conjunctiva was swabbed (four times)
with one side of the swab to collect cells from the entire
exposed surface. The swab was then turned over and the
swabbing was repeated to cover the upper conjunctival
surface. Samples were placed in a sterile tube, which was
then tightly closed. The tubes were frozen and shipped on dry
ice to the Chlamydia National Reference Centre (Bordeaux,
France) for analysis. The period between specimen collection
and testing was 3 months.
DNA extraction
Dry swabs were placed in 0.5 mL of sucrose phosphate (2-SP
medium). Aliquots (200 lL) of 2-SP medium were extracted
using the MagNA Pure LC Robot (Roche Molecular Systems,
Pleasanton, CA, USA) and the MagNA Pure LC DNA isolation
kit I [10]. The distribution of samples into sample cartridges
was carried out under a vertical laminar ﬂow, and the
extraction was performed in a closed chamber to avoid
cross-contamination. Extracted DNA was ready for ampliﬁca-
tion by the real-time PCR assays targeting the omp1 gene and
human chromosomal DNA, but required dilution in a speciﬁc
buffer for the Cobas Amplicor assay.
Qualitative PCR targeting the C. trachomatis plasmid
All specimens were tested using the Cobas Amplicor CT ⁄NG
assay (Roche Diagnostics, Mannheim, Germany). Extracted
DNA (30 lL) was mixed with 30 lL of the diluent (Amplicor
CT ⁄NG preparation kit), and 50 lL of this mix was then added
to 50 lL of Mastermix. Dilution and distribution were carried
out under a vertical laminar ﬂow in a closed system. An
internal control was systematically ampliﬁed in each sample
together with the speciﬁc plasmid target. If the internal control
did not amplify, samples were retested after heating at 90C
and diluting ten-fold to remove inhibitors. Positive and
negative controls were included in each test series. After
testing, sample containers were discarded unopened.
Quantitative in-house real-time PCR targeting the omp1
gene of C. trachomatis
A set of primers [11] bracketing a 129-bp fragment of the omp1
gene coding for the main outer-membrane protein was used to
amplify the serovars known to be associated with trachoma.
This omp1 real-time PCR was used to quantify the C. tracho-
matis load in samples and to monitor the efﬁciency of
extraction and the presence of inhibitors. Real-time PCR was
performed using the ABI Prism 7000 system (Applied Biosys-
tems, Courtaboeuf, France), with 5 lL of DNA extracted by the
MagNA Pure added to 20 lL of qPCR Mastermix Plus for
SYBR Green (Eurogentec, Seraing, Belgium). For quantiﬁca-
tion, a plasmid carrying the ampliﬁed fragment (pOMP) was
constructed and used to generate a standard curve. The
estimated load of C. trachomatis was expressed as the number
of copies of the omp1 gene. The detection limit of this method
was 0.2 copies ⁄ assay, corresponding to ten copies in the
original sample.
Quantiﬁcation of human DNA in samples
An assessment of cell numbers served as an indicator of the
efﬁciency of the conjunctival swabbing and of the ability to
detect intracellular bacteria. The gene coding for the human
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telomerase reverse transcriptase hTERT is present as a single
copy in each human cell, and was ampliﬁed using the
Quantiﬁler Human DNA Quantiﬁcation Kit (Applied Biosys-
tems) according to the manufacturer’s instructions. Cellular
DNA contained in the sample was expressed in terms of
ng ⁄ lL. The correlation between negative PCR results and the
epithelial cell load in the swabs (i.e., the quality of the samples)
was investigated by comparing the cell load values for swabs
from villages with no positive C. trachomatis PCR results with
those from villages with a high prevalence.
Controls
Choice of the cryptic plasmid as target. Specimens obtained from
villages in which all results were negative were analysed using
the omp1 real-time PCR to determine whether the negative
results were a consequence of the absence of the target cryptic
plasmid in the circulating strains [12,13].
DNA extraction yield and potential retention of DNA by the Dacron
swabs. Known quantities of omp1 DNA target (ten-fold dilu-
tions of pOMP DNA) were applied to Dacron swabs, dried,
and then recovered into the transport medium by vortexing.
Simultaneously, identical quantities of pOMP DNA were
added directly to transport medium. DNA from both speci-
mens was extracted as described above. Assays were per-
formed in duplicate using 103)50 copies ⁄ assay. The cycle
threshold, i.e., the number of cycles necessary to observe the
start of ampliﬁcation, was determined.
Absence of inhibitors. To assess whether the extraction method
had removed possible PCR inhibitors, pOMP DNA (106 and
50 copies ⁄ 200 lL) was added to ten negative samples selected
from villages in which all results were negative and ten
negative samples from villages with high positive rates. The
samples were then extracted by MagNa Pure, and ampliﬁed by
the quantitative PCR.
Statistical analysis
Student’s t-test was used for analysis of numerical variables.
RESULTS
Population sampled
Every effort was made to screen all children aged
1–10 years in each village. In the Kankan region
(Guinea Conakry), 7698 children were screened
and 848 were diagnosed clinically with active
trachoma. The overall prevalence of active tra-
choma was 11%, ranging from 5% to 23% among
villages. In total, 552 children from 21 Guinean
villages were sampled for PCR analysis. In Pakis-
tan, 4300 children were screened in schools,
attended mostly by boys in Rawalpindi and
Attock districts, among whom 120 were diag-
nosed clinically with active trachoma. The overall
prevalence of active trachoma was 2.8% (ranging
from 0% to 16% among villages). In total, 118
children from six Pakistani villages were sampled
for PCR analysis.
Detection rate of C. trachomatis
PCR results were positive for 153 (23%) children in
at least one eye: 128 (23.2%) of 552 in Guinean
villages and 25 (21.2%) of 118 in Pakistani villages.
Positive sample rates for each village are shown in
Table 1. InGuinea, the positivity rates ranged from
0% in four villages (Balangoudou, Djoumawalia,
Loba and Koba) to 65% (Kinieba). In Pakistan,
positivity rates ranged from 0% (Maira Sharif) to
43% (Jaba). According to the quantitative real-time
PCR assay targeting the omp1 gene, the majority
(132 ⁄ 153) of children with C. trachomatis detected
in both eyes had amean load of c. 108 copies ⁄ swab,
whereas the 21 children with C. trachomatis detec-
ted in only one eye had a mean load of c. 103 cop-
ies ⁄ swab (p <10)6). Among these 21 children, the
samples from the other eye of ﬁve children were
negative by the in-house real-time PCR and posit-
ive by Cobas Amplicor, indicating a load of <10
copies ⁄ swab. In Minima and in Missamana (Haute
Guinea), the mean conjunctival bacterial load
attained levels of 109)1010 copies of C. trachomatis ⁄
swab, and >50% of the children sampled in both
villages were PCR-positive.
Controls for PCR-negative specimens
As all swabs were obtained from children diag-
nosed clinically with trachoma, the PCR results
indicated a need to check the quality of the
conjunctival swabbing and the PCR efﬁciency
with respect to the PCR target, DNA extraction
and possible inhibition.
The load of human cells in the samples
obtained from two different Guinean villages,
one with a high rate of positive PCR results
(Sontila, 62.5%) and one with a low rate (Solo,
12.5%), was compared with the load in samples
obtained from four negative villages (Balandou-
gou, Djoumawalia, Loba and Koba). The results
(Table 2) showed variations in human DNA
content, from 0 to 100 ng ⁄ lL. The mean human
DNA content was signiﬁcantly higher for the
Sontila and Solo samples than for the four
‘negative’ villages (p 0.048), suggesting that a
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reduced number of human cells was present in
the conjunctival swabbings from the four ‘negat-
ive’ villages.
The hypothesis that C. trachomatis strains circu-
lating in the ‘negative’ villages might lack the
cryptic target plasmid was refuted by the fact that
the omp1 PCR results were also negative. The
experiments to assess DNA retention showed no
signiﬁcant differences in the number of DNA
copies for the plasmid dilutions tested (Table 3),
Table 1. Distribution and Chlamydia trachomatis load (copies of the omp1 gene ⁄ swab) for PCR-positive individuals in
villages in Guinea and Pakistan
Location
No. of individuals
tested
No. of PCR-positive
individuals
Mean load with both eyes
positive
Mean load with
one eye positive Positive (%)Left eye Right eye
Villages in Guinea
Fode cariah 31 3 106 2 · 106 – 12.9
1 – – 2 · 103
Batenafadji 26 1 103 4 · 105 – 7.69
1 – – 2 · 104
Batesoyla 41 3 105 6 · 105 – 9.76
1 – – 5 · 102
Dalaba 38 2 5 · 106 5 · 106 – 7.9
1 – – 3 · 102 28.57
Kiniero 55 4 6 · 104 9 · 104 – 7.27
Ourembaya 35 7 4 · 106 2 · 106 – 28.57
3 – – 2 · 103
Balangoudou 22 0 – – – 0
Kotero 14 2 106 8 · 104 – 14.3
Kinieba 26 15 6 · 106 6 · 106 – 65.4
2 – – 3 · 103
Djimbala 39 21 6 · 106 6 · 106 – 61.53
3 – – 103
Minima 29 15 4 · 109 3 · 109 – 51.7
Missamana 29 16 5 · 109 1010 – 58.6
1 – – 6 · 103
Sontila 16 7 5 · 106 4 · 106 – 62.5
3 – – 5 · 104
Djoumawalia 25 0 – – – 0
Solo 16 2 2 · 106 2 · 106 – 12.5
Djansoumana 18 1 4 · 105 107 – 5.55
Loba 11 0 – – – 0
Koba 12 0 – – – 0
Kassa 15 2 2 · 104 5 · 104 – 13.33
Moussaya 27 2 5 · 105 106 – 11.11
1 – – 2 · 102
Doutilaba 27 7 3 · 105 7 · 105 – 29.62
1 – – 104
Total 552 128 5 · 108 8 · 108 9 · 103 23.2
Villages in Pakistan
Sujenda 27 9 109 2 · 109 – 33
Chura Sharif 13 1 – – 5 · 103
Jaba 21 7 2 · 105 2 · 105 – 42.86
2 – – 5 · 103
Malhowali 29 5 4 · 106 2 · 107 – 17.2
Maira Sharif 14 0 – – – 0
Girdi 14 1 104 102 – 7.1
Total 118 25 3 · 108 5 · 108 5 · 103 21.2
Table 2. Human DNA content (ng ⁄ lL) in selected samples
Villages with positive PCR results Villages with no positive PCR results
p valueVillage n Mean ± SD Median Min. Max. Village n Mean ± SD Median Min. Max.
Sontila Balangoudou 44 21.4 ± 24.2 14.8 0 95.3
Negative 15 28.6 ± 30.8 21.6 1.1 116.2 Djoumawalia 52 19.4 ± 21.9 10.1 0.1 76.0
Positive 17 34.6 ± 28.8 26.9 0 94 Koba 24 23.4 ± 22.5 13.4 0.3 75.1
Solo Loba 22 14.5 ± 17.6 7.7 0.5 57.8
Negative 28 25.3 ± 36.4 5.7 0.262 115.1
Positive 4 9.4 ± 7.8 9.0 0.6 19
Total 64 27.6 ± 31.9 17.8 0 116.2 Total 142 20 ± 22.1 11.2 0 95.3 0.048a
aStudent’s t-test.
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indicating that DNAwas released completely from
the swabs into the transport medium. When large
amounts of target DNA (106 copies ⁄ sample) were
added, no statistically signiﬁcant differences were
observed between the villages with no positive
results and the village with high positive detection
rates, with the mean cycle threshold value for
negative samples from ‘negative’ villages being
equal to that of negative samples fromvillageswith
high positive detection rates (22.3 ± 0.2 and
23.3 ± 0.8, respectively). However, for six of ten
samples to which only a small quantity of target
DNA (50 copies ⁄ tube) was added, a difference of
about three cycles, corresponding to a ten-fold loss
of sensitivity, was observed. For the seventh
sample, the target was not detected at all. These
results suggest that samples containing a reduced
number of DNA copies may produce randomly
distributed false-negative PCR results.
DISCUSSION
This study revealed an overall detection rate of
23% for C. trachomatis among children with clin-
ically active trachoma in Guinea and Pakistan.
The positivity rates varied widely among regions
and villages, despite clinical signs in all the
sampled children. A similar large variability has
been reported previously in other countries [14].
Moreover, in the present study, 21 of 153 children
were PCR-positive for C. trachomatis in only one
eye, indicating the possibility of unilateral infec-
tion [15]. Nevertheless, bacteriological and clinical
results do not always correlate, particularly in
areas with a low prevalence of trachoma [16], as
in the present study, and particularly in Pakistan,
where the overall prevalence was 2.7%. In Nepal,
which is a low-prevalence region with 6% of
children with active disease, Baral et al. [17] failed
to detect C. trachomatis in any children with signs
of active trachoma, while Burton et al. [4] found
detectable infection in less than a quarter of
clinically active cases, and less than a quarter of
infected individuals had signs of active disease.
Wright and Taylor [18] considered that these
ﬁndings were explained largely by the kinetics of
infection and the appreciation of clinical signs, as
opposed to problems inherent to either detection
system. However, the discrepancies between the
observation of clinical symptoms and the detec-
tion of C. trachomatis raise questions concerning
the reliability of current laboratory methods.
Many factors can inﬂuence the quality of PCR
results, including the efﬁciency of sampling and
the PCR itself. In the present study, sampling was
performed by conjunctival swabbing rather than
by conjunctival scraping. Swabbing is considered
to be less traumatic and less painful, and does not
require local anaesthetic or post-sampling treat-
ment with broad-spectrum antibiotics. All the
samples were collected under strict hygienic
conditions in order to avoid cross-contamination,
and all the control samples taken from the air, the
working surfaces and staff were negative. Most
previous surveys have not reported on the pre-
cautions taken during the clinical diagnosis and
sampling procedures. Solomon et al. [14] used
stringent measures to avoid cross-contamination,
and the results obtained (33% of positive samples
from patients with follicular conjunctivitis ⁄
trachomatous inﬂammation) were similar to those
of the present study.
Since the probability of collecting C. trachomatis
from the conjunctiva may depend on the con-
junctival bacterial load (which itself depends on
the stage of the infection and on the inﬂammatory
status), as well as the quality of the conjunctival
swabbing, the concentration of cell DNA present
in the specimens was determined. The results
showed up to 100-fold variability among individ-
uals, and sufﬁcient quantities of cells were not
always collected. These results suggest a need to
assess the quantity of human cells present
in negative PCR assays for C. trachomatis with
samples from patients presenting with clinically
active trachoma.
Although the cryptic plasmid of C. trachomatis
appeared to be a satisfactory target for the diag-
nosis of trachoma, the reproducibility of the
qualitative PCR technique used in this study
was sub-optimal for samples containing low
Table 3. Analysis of DNA retention in Dacron swabs by
quantiﬁcation of pOMP DNA dilutions using real-time
PCR
Quantity of omp1 target
(copies ⁄ assay)
Ct mean ± SDa
Condition 1b Condition 2c
5000 24.8 ± 0.1 25.1 ± 0.07
500 28 ± 0.2 29 ± 0.2
50 31.3 ± 0.6 31.9 ± 0.2
aAll tests were performed in duplicate.
bTarget placed directly in sucrose phosphate (2-SP) medium and extracted.
cTarget placed on Dacron swab, released by vortexing into 2-SP medium and
extracted.
Ct, cycle threshold (i.e., no. of cycles necessary to observe the start of ampliﬁcation).
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chlamydial loads, as has been reported previously
[8]. However, as also reported previously [14], the
Cobas Amplicor assay was more sensitive than the
C. trachomatis quantitative real-time PCR [15]. This
difference in sensitivity could be associated with
the volume of DNA extract used for each assay
(5 lL for the quantitative real-time PCR vs. 25 lL
for the Cobas Amplicor assay), or the fact that the
Cobas Amplicor assay detects a multicopy gene
present in the plasmid and not a single-copy
structural gene. Overall, the C. trachomatis loads
detected in the present study were high
(c. 108 copies ⁄ swab), with a range similar to load
levels described previously in children with clin-
ical evidence of active disease [19]. In cases of
unilateral infection, the C. trachomatis load was
signiﬁcantly lower. Thus, the mean count was
signiﬁcantly different when C. trachomatis infec-
tion was bilateral or unilateral, suggesting that
both eyes should be tested (pooled or separately)
in individuals with a clinical diagnosis of active
trachoma. The detection rate found in the present
study may reﬂect a realistic picture, considering
the extensive precautions taken to avoid (cross-)
contamination and the numerous PCR controls
that were included. The possible false-negative
PCR results seemed to be a consequence of the lack
of effectiveness of the sampling procedures, and
not a technical problem with the PCR itself.
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